ReviewFrontiers in microbiology2018
Drug Resistance in
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 209 citations in OpenAlex.
- ROP64-DeficientMicroorganisms · 2026Article
- Minimum Inoculum of Resistance Assay for Evaluating Antitoxoplasmosis Compounds That Target Phenylalanine tRNA Synthetase.ACS infectious diseases · 2026Article
- Quercetin ReducesInternational journal of molecular sciences · 2026Article
- Legacy 4(1ACS infectious diseases · 2026Article
- Myricetin InhibitsCells · 2026Article
- Inhibitors of the FASII Metabolic Pathway inMicroorganisms · 2026Review
- Minimum inoculum of resistance assay for evaluating for anti-toxoplasmosis compounds that target phenyl alanine tRNA synthetase.bioRxiv : the preprint server for biology · 2026Article
- Effects of Toxoplasma Gondii Type II Infection on Serum Serotonin Concentration and Indoleamine 2,3-Dioxygenase Gene Expression in Balb/c Mice.Acta parasitologica · 2026Article
- Oxadiargyl analogs as potent inhibitors ofRSC medicinal chemistry · 2026Article
- Evolution ofJournal of parasitology research · 2026Review
- Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis.Frontiers in immunology · 2026Article
- Total RNA and MicroRNA Transcriptomic Responses of Human Retinal Müller Glial Cells to Infection withOphthalmology science · 2026Article
- Cerebral toxoplasmosis: Parasitology, diagnosis, treatment, and prevention - a narrative review.Current research in parasitology & vector-borne diseases · 2026Review
- Emerging Ocular Pathogen Resistance and Clinically Used Solutions: A Problem That Is More than Meets the Eye.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
- Exploring the role of chitosan and curcumin-loaded chitosan nanoparticles against chronic toxoplasma infection in experimental mice.Scientific reports · 2025Article
- Linalool as a potential agent against Toxoplasma gondii: an in vitro study.BMC research notes · 2025Article
- Therapeutic Effect of Allium sativum (Garlic) Extract Using Nanotechnology on Murine Chronic Toxoplasmosis.Acta parasitologica · 2025Article
- A nucleoside transporter on the mitochondria of T. gondii is essential for maintaining normal growth of the parasite.Parasites & vectors · 2025Article
- Recombinant ROP6 protein expressed in Saccharomyces cerevisiae INVSc1 cells induced strong immune response and provided significant protection against toxoplasmosis.Scientific reports · 2025Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.